Lupin Project
-
Upload
abhishek-pandey -
Category
Documents
-
view
270 -
download
2
description
Transcript of Lupin Project
LUPIN Pharmaceuticals, Inc.
Presented by-Abhishek Pandey15020241005
Submitted to-Prof. Smita SantokiTowards Operations Assignment
About Lupin
• Established in 1968, by Dr. Deshbandu Gupta
• Company named after Lupin flower, which is known for its theraupatic nature.
• First gained reputation as the largest supplier of TB drugs
• Today is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol reducing agents) and has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy
• For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively
• World leader as “branded generics"
“Mission/Vision
Lupin's mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of
branded and generic products in key markets.
Products
Generics Specialty API• More than 75 FDA
approved products• ANDAs in following
areas- a. cephalosporinsb. Cardiovascularc. Controlled release ANDAd. Paragraph IVs
• Committed to child care
• Drug - SUPRAX®• Dedicated sales
force to call upon pediatricians
• leading manufacturer of cephalosporin API’s
• wide range of ACE-inhibitors and cholesterol reducing agents
Market Watch
Global Capabilities footprint
Global HQ, Mumbai
Market Presence
2004 Lupin was operating only from India. Its presence to other countries was through trade partnerships and direct-to-market initiatives
2005 Lupin was the last entrant into US market amongst Indian Pharma majors
2007 acquired Kyowa in 2007 to enter Japanese market
2008 bought Hormosan Pharma GmbH to improve its position in Europe. This has helped in strenghtening its presence in European markets
Lupin acquired Generic Health to enter into Australian markets
2009 Acquires Multicare Pharma in Philippines to penetrate into SE Asia
2011 Acquires I’rom in Japan to break into top 10 generic brands in Japan
Growth through M&A
2012 Enters strategic marketing parnership with Sanofi to foray into neurology (Philipines)
2014 entered into JV with Yoshindo to create YL Biologics. This is to develop its portfolio in biosimilars
Acquires Laboratories Grin in Mexico to serve Mexico and Latin America
bought Gavis to become the 5th largest pharma company in US
2015 bought 40% stake of Pharma Dynamics in South Africa. This has made it the 4th largest generic company in SA
Buys Medquímica Indústria Farmacêutica, Brazil for further penetration in Latin America
Purchases Biocom, to foray into Russian market
Growth through M&A (contd.)
Growth Drivers
Organic Inorganic
Maximizing current / near term pipeline
Operational / Commercial excellence
Pipeline evolution into complex generics / specialty
Leveraging our investments across geographies
Specialty
Geographic diversification
Tech Platforms
Scale
Growth strategy
US India Japan Europe Other Markets• Entry through
generic drugs• Expansion
through strategic acquisitions
• Portfolio expansion through R&D in Pune
• New therapy areas
• Entry through generic drugs
• Expansion through strategic acquisitions
• Biosimilar through JV
• Entry through trade partners
• German acquisition helps in central distribution
• Establish trade partners
Operational Strategy• Vertically Integrated and diversified manufacturing platform
• Control over entire supply chain right from earlyintermediates
• Ability to manufacture key products from two or more sites
• Extensive capabilities in multiple dosage forms – solids,semi-solids, liquids, injectables and more
• Consistent Compliance track record
• Responsive and agile supply chain
• Differentiated market entry approach
• Focus on margin enhancement and overhead optimization
• Challenges – to cater the growing new markets
Latest in Media!
Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules in the US (September 3rd, 2015)
Pharma major Lupin Limited announced today that its subsidiary Lupin Pharmaceuticals, Inc. (Lupin) has launched its Duloxetine 40 mg Delayed-Release (DR) Capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength. Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment.
Lupin is the only generic manufacturer to offer all Duloxetine dosage strengths - the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin's generic Duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength.
Cymbalta® Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths had annual U.S sales of approximately USD 1.05 billion (Brand + Generics - IMS MAT June 2015).
Bibliography
• http://www.lupinpharmaceuticals.com/
• http://www.lupinpharmaceuticals.com/newsroom.htm
• http://articles.economictimes.indiatimes.com/2010-04-30/news/27578338_1_kamal-k-sharma-lupin-generic-players
• http://www.pharmacytimes.com/publications/supplement/2012/Generic-Supplement-2012/LupinPharmaceuticals_2012
• http://old.businessworld.in/news/business/pharma/how-lupin-got-its-mojo-back/379072/page-1.html
• http://www.thehindubusinessline.com/companies/lupin-looks-at-bigticket-alliances-acquisition-in-india/article2415313.ece
• https://en.wikipedia.org/wiki/Lupin_Limited
Thanks!Any questions?
You can find me at:[email protected]